Cases & Deals

  • Home
  • Practices
  • Tallac Therapeutics seeks global patent protection relating to antibody-oligo conjugates

Share

Tallac Therapeutics seeks global patent protection relating to antibody-oligo conjugates

September 2019

Client(s) Tallac Therapeutics, Inc.

Jones Day represented Tallac Therapeutics, Inc. in the establishment of global patent portfolios relating to antibody-oligonucleotide immunoconjugates for the treatment of cancer.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.